Healthcare / BiotechnologyTokyo
$1039.00
+32.00 (+3.18%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $28.1M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.3B
P/E
20.5x
↑EV/EBITDA
3.2x
↓ROE
13.7%
↑Gross Margin
45.4%
↓Debt/Equity
0.41
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+9.7%
FCF CAGR
-63.1%
FCF margin
0.5%
FCF / Net income
0.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.21B · net income $794.8M · FCF $28.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.21B | $5.21B | $4.77B | $4.74B | $3.95B |
| Net Income | $794.8M | $794.8M | $385.0M | $829.8M | $587.7M |
| EBITDA | $1.41B | $1.41B | $958.1M | $1.44B | $1.14B |
| EPS | 157.57 | 157.57 | 92.43 | 199.23 | 117.18 |
| Gross Margin | 45.4% | 45.4% | 39.4% | 51.7% | 51.7% |
| Operating Margin | 19.0% | 19.0% | 12.5% | 26.7% | 24.6% |
| Net Margin | 15.3% | 15.3% | 8.1% | 17.5% | 14.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.41 | 0.41 | 0.74 | 0.70 | 1.01 |
| Current Ratio | 1.80 | 1.80 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $28.1M | $28.1M | $260.9M | $-99.6M | $559.4M |
| Returns | |||||
| ROE | 13.7% | 13.7% | 11.5% | 27.5% | 26.5% |
| Valuation | |||||
| P/E | 20.49 | 20.49 | — | — | — |
| EV/EBITDA | 3.18 | 3.18 | — | — | — |
| P/B | 0.91 | 0.91 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 9.1% | 9.1% | 0.6% | 20.2% | — |
| EPS Growth | 70.5% | 70.5% | -53.6% | 70.0% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-16.4%
EPS terminal req.
$92.19
Spread vs growth
86.8%
5Y implied EPS CAGR
-6.7%
EPS terminal req.
$111.55
Spread vs growth
77.1%
10Y implied EPS CAGR
1.3%
EPS terminal req.
$179.66
Spread vs growth
69.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.1%
Start / end P/E
18.2x → 6.6x
EPS bridge
92.43 → 157.57
Residual
-44.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.